NCT04252885View on ClinicalTrials.gov

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

May 31, 2020

Conditions
Coronavirus Infections
Interventions
DRUG

Lopinavir and Ritonavir Tablets

As indicated in arm/group descriptions

DRUG

Arbidol

As indicated in arm/group descriptions

Trial Locations (1)

510060

Guangzhou Eighth People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangzhou 8th People's Hospital

OTHER

NCT04252885 - The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection | Biotech Hunter | Biotech Hunter